In order to facilitate individualized anti-PD1/PDL1 therapy, our study aims to predict cancer immune characteristics and patient prognosis during anti-PD1/PDL1 therapy by integrating cancer stemness and TNB features. This evidence concerns the gene CD274 and cancer.